CG Oncology's cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trial
CGON•CG Oncology said its Phase 3 PIVOT-006 trial found cretostimogene reduced bladder cancer recurrence risk by 68%; the results are expected to support a second biologics license application in Q2 2027.
1. Trial results
CG Oncology's Phase 3 PIVOT-006 trial found that cretostimogene significantly reduced recurrence in intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer, cutting recurrence risk by 68%. The treatment was generally well tolerated, with no treatment-related discontinuations.
2. Planned filings
Topline results are scheduled for presentation at the Society of Urologic Oncology Annual Meeting on December 2, 2026. CG Oncology expects to submit a second biologics license application for intermediate-risk and high-grade Ta disease in Q2 2027; following FDA feedback, its initial application for BCG-unresponsive disease will add high-grade papillary-only disease, with completion expected by the end of March 2027.




